The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson
CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
 
Catherine A. Shu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech/Roche
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Janssen (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Koichi Goto
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; MSD K.K.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Frank Griesinger
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol Myers Squibb; Genzyme; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; Novartis; PeerVoice; Pfizer; Prime Oncology; Roche; Springer; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
John Xie
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Jun Chen
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Janine Mahoney
No Relationships to Disclose
 
Meena Thayu
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson/Janssen; Johnson & Johnson/Janssen (I)
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
 
Leonardo Trani
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Joshua Bauml
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Foundation Medicine; Genentech; Guardant Health; Inivata; Janssen; Merck; Novartis; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)